RAD.AX - Radiopharm Theranostics Limited
| Previous close | 0.1300 |
| Open | 0.1400 |
| Bid | 0.1400 x N/A |
| Ask | 0.1450 x N/A |
| Day's range | 0.1400 - 0.1500 |
| 52-week range | 0.1000 - 0.2500 |
| Volume | |
| Avg. volume | 329,671 |
| Market cap | 49.2M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high unmet needPotential follow-on indications include non-small cell lung cancer, head and neck, and colorectal cancer SYDNEY, Australia, May 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic a
- GlobeNewswire
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
Agreement will supply Tb-161 for RAD 602, a potential first in class radiopharmaceutical for treatment of brain cancersSYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an agreement with TerThera to supply the Company with Terbium-161 (Tb-161). The Tb-161 isotope will be linked to a proprietary peptide to form RAD 602,
- GlobeNewswire
Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit
SYDNEY, Australia, March 28, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the Company will participate in Jefferies Inaugural Radiopharma Innovation Summit being held in New York City on April 3rd, 2023. Riccardo Canevari, Chief Executive Officer and Managing Director of Radiopharm Theranostics, and Vittorio Puppo, Chief Operating Officer
- GlobeNewswire
Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate
- GlobeNewswire
Dr Ken Herrmann Appointed to RAD Scientific Advisory Board
SYDNEY, Australia, March 03, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB). Dr Herrmann is a certified Nuclear Medicine physician who also holds an executive MBA from the University of Zürich and currently serves as Chair of the Departm
- GlobeNewswire
Radiopharm Theranostics Initiates Process for Nasdaq Listing
Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023 SYDNEY, Australia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced the initiation of the process to obtain a secondary listing on the Nasdaq Capital Market. The Company has filed a registr
- Business Wire
Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
SYDNEY & BELOIT, Wis., October 26, 2022--Radiopharm Theranostics signed an agreement with NorthStar Medical Radioisotopes for supply of therapeutic radioisotope non-carrier-added Actinium-225
- PR Newswire
PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London's F-18 Pivalate (RAD 101) has achieved successful Phase 2a data in patients with brain metastases, having shown significant tumour uptake that was consistent and independent from the tumour origin.
- PR Newswire
Radiopharm Theranostics and SHINE Technologies Announce Clinical Supply Agreement for Cancer-Fighting Medical Isotope
SHINE Technologies, a next-generation fusion technology company, and Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, today announced that they have entered into a clinical supply agreement. SHINE will supply Radiopharm with isotope non-carrier-added lutetium-177 (Lu-177).
- PR Newswire
MD ANDERSON AND RADIOPHARM THERANOSTICS LAUNCH JOINT VENTURE TO DEVELOP NOVEL RADIOPHARMACEUTICALS
The University of Texas MD Anderson Cancer Center ('MD Anderson') and Radiopharm Theranostics Limited ('Radiopharm')(ASX: RAD) today announced the launch of Radiopharm Ventures, LLC, a joint venture company created to develop novel radiopharmaceutical therapeutic products for cancer.
- GlobeNewswire
Diamond Equity Research Releases Update Note on Radiopharm Theranostics Limited (ASX: RAD)
NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released update note on Radiopharm Theranostics Limited (ASX: RAD). The update note includes information on the Radiopharm Theranostics’ financial results, management commentary, recent developments, outlook, risks, and our revised valuation estimates. The update note is available here. Highlights from the note include: Key partnerships aid
- PR Newswire
RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that it has entered a collaboration agreement with Lantheus for the mutually beneficial development of NM-01, a nanobody made using genetically engineered camelid derived single domain antibodies, that can be labelled with radioisotopes to potentially diagnose and treat multiple tumor types.
- GlobeNewswire
UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022
Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on June 23, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty-five-minu
- PR Newswire
RAD adds brain tumor technology to portfolio
Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a world-class developer of cutting-edge radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that it has signed an exclusive sublicensing agreement with NeoIndicate, LLC ("NeoIndicate") to a PTPµ-targeted radiopharmaceutical agent, which was developed at CWRU in Ohio, USA.
